Navigation Links
AIT Laboratories Expands Pharma Services
Date:9/22/2008

Names Industry Veteran as Executive Director

INDIANAPOLIS, Sept. 22 /PRNewswire/ -- AIT Laboratories, a leading forensics, pain management, clinical, and pharmaceutical testing facility, is announcing the expansion of its pharmaceutical services and has chosen an industry veteran to lead the division. AIT has named Ronald Shoup, former co-founder and chief scientific officer of West Lafayette-based Bioanalytical Systems, Inc. (Nasdaq: BASI), as its executive director of Pharma Services. "Ron brings 30 years of leadership, entrepreneurship, and scientific expertise to AIT as we look to expand our facility to meet the growing needs of the Pharma industry," said AIT President and CEO Michael A. Evans, Ph.D.

AIT supports clinical trials through its current drug analysis services and expects to offer regulated bioanalytical services for preclinical development in the future. Almost 20 years of experience in sample management enables AIT to offer the highest quality of organization for the collection, distribution, maintenance, and reconciliation of samples from clinical studies. As a premier leader in the application of mass spectrometry for biological samples, AIT routinely develops, validates, and performs mass spectrometry analysis in support of new drug development.

"My experience in analytical chemistry, regulatory audits, and the Pharma/biotech industry has given me challenging opportunities to solve scientific problems in drug development," said Shoup. "I know that my skills can help AIT to further enhance its success and reputation in the industry."

As pharmaceutical companies are going more towards their core business of making drugs, AIT is filling a need of providing superior bioanalytical tes
'/>"/>

SOURCE AIT Laboratories
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Codexis Appoints Singapore Laboratories Managing Director
2. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
3. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
4. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
5. Stiefel Laboratories Appoints Two New Members to Board of Directors
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
7. ARUP Laboratories Releases ARUP Consult(R) 2.0
8. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
9. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
10. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
11. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3
(Date:12/4/2009)A major discovery is challenging accepted thinking about amyloids the fibrous protein deposits associated with diseases such as Alzheimer,s and Parkinson,s and may open up a potential new area for t
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
Breaking Biology News(10 mins):New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2Species down, disease up 2Species down, disease up 3Species down, disease up 4Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 1Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 2Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 3Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 4Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 5Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 6Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 7Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 8Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 9Hormones May Affect Neurological Disease Risk 50513 1Hormones May Affect Neurological Disease Risk 50513 2Antibiotics May Boost Risk for Recurrent Ear Infection 50511 1Antibiotics May Boost Risk for Recurrent Ear Infection 50511 2
Mouse Anti-Mannose Receptor Monoclonal Antibody, Biotin Conjugated, Clone 15-Feb from Abcam
TE Buffer from Upstate
Mouse Anti-DcR1 Monoclonal Antibody, Biotin Conjugated, Clone DJR3 from Abcam
L-Selenomethionine from Calbiochem
Biology Products: